What is Roth Capital’s Estimate for BRTX Q1 Earnings?

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Stock analysts at Roth Capital issued their Q1 2025 earnings estimates for BioRestorative Therapies in a note issued to investors on Tuesday, November 5th. Roth Capital analyst J. Aschoff expects that the company will post earnings of ($0.34) per share for the quarter. The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.83) per share. Roth Capital also issued estimates for BioRestorative Therapies’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.27) EPS, FY2027 earnings at $2.47 EPS and FY2028 earnings at $5.43 EPS.

Separately, Roth Mkm boosted their price objective on BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th.

BioRestorative Therapies Price Performance

Shares of NASDAQ BRTX opened at $1.55 on Wednesday. The stock has a market capitalization of $10.73 million, a PE ratio of -0.76 and a beta of 63.40. BioRestorative Therapies has a one year low of $1.03 and a one year high of $3.67. The business’s fifty day moving average price is $1.64 and its 200-day moving average price is $1.58.

BioRestorative Therapies (NASDAQ:BRTX) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.06. BioRestorative Therapies had a negative return on equity of 107.65% and a negative net margin of 6,898.28%. The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.03 million. During the same quarter in the prior year, the business earned ($0.77) earnings per share.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.